Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
NCT06169150 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350
Last updated 2025-09-25
Summary
Background:
Immune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological disease may have defects in their immune system.These complications can affect many body functions, including how they move, walk, think, and feel. Researchers do not fully understand how immune diseases affect the nervous system. By learning more, they hope to create more effective treatments.
Objective:
To learn more about the interaction between immune and nervous system and how immunity disease affect the nervous system.
Eligibility:
People aged 2 years and older with an immunity disease. Their healthy biological relatives and other healthy volunteers are also needed.
Design:
Participants will be screened. Blood will be drawn for research. They may have imaging scans. Adults may undergo lumbar puncture: A needle will be inserted into their back to collect fluid from the space around the spinal cord. The imaging scans and lumbar puncture will be optional for healthy relatives and volunteers.
All participants will have 1 study visit per year for 5 years.
They will be asked to donate samples of body fluids at each visit. Blood samples are required for the study. All other donations are optional. These may include saliva, urine, breast milk, stool, vaginal secretions, and wound drainage.
Affected participants may be asked for a skin biopsy: A small sample of skin will be removed. They may also be photographed or videotaped to record the symptoms of their disease.
Tests for each study visit may be spread over several days, if needed.
Visits may be at the clinic. Participants may also collect their own samples at home and send them to the researchers....
Conditions
- Nervous System Disease
- Immune System Disease
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Farinaz Safavi, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 2 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-01-12
- Primary Completion
- 2043-01-01
- Completion
- 2043-10-01
Countries
- United States
Study Locations
More Related Trials
-
A Registered Cohort Study of Immune-Mediated Neuropathies
NCT04292834 ·Status: UNKNOWN
-
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
NCT01655394 ·Status: UNKNOWN
-
Markers of Favorable Response to Complement Inhibitors Therapy
NCT06455709 ·Status: RECRUITING
-
Markers of Favorable Response to FcRn Inhibitors(INFORM)
NCT06685055 ·Status: RECRUITING
-
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
NCT05219383 ·Status: NOT_YET_RECRUITING
-
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
NCT05357781 ·Status: RECRUITING
-
A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies
NCT00006072 ·Status: UNKNOWN ·Phase: PHASE2
-
Predictive Factors of Long Term Outcome in MMN
NCT04015934 ·Status: COMPLETED
-
Immunoglobulin Dosage and Administration Form in CIDP and MMN
NCT02111590 ·Status: COMPLETED
-
Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing
NCT04356781 ·Status: COMPLETED
-
Meningococcal Vaccination in Patients on Complement Inhibitors
NCT06906692 ·Status: ACTIVE_NOT_RECRUITING
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
NCT01623076 ·Status: ACTIVE_NOT_RECRUITING
-
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
NCT03864185 ·Status: COMPLETED ·Phase: PHASE2
-
RWE-based Treatment Patterns and Outcomes in CIDP
NCT05940922 ·Status: UNKNOWN
-
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
NCT04708626 ·Status: COMPLETED
-
Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies
NCT05966350 ·Status: COMPLETED
-
Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk
NCT02440126 ·Status: COMPLETED
-
EVALUATION OF SERUM INFLAMMATORY CYTOKINE CONCENTRATION IN HEREDITARY SENSITIVOMOTOR NEUROPATHIES
NCT06808581 ·Status: COMPLETED ·Phase: NA
-
Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy
NCT00268788 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Profiles in Myasthenia Gravis
NCT05095103 ·Status: UNKNOWN
-
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
NCT00619671 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
NCT06844864 ·Status: ACTIVE_NOT_RECRUITING
-
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
NCT02797080 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy
NCT00004286 ·Status: COMPLETED ·Phase: PHASE3
-
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945 ·Status: ACTIVE_NOT_RECRUITING